Marcus Hompesch is an expert in Internal medicine at ProSciento, Inc. (United States). As of October 2026, ScienceLeadR ranks Marcus Hompesch in the top 1% of experts worldwide for Glucose Metabolism Disorders and Diabetes Mellitus. Marcus Hompesch has authored 106 publications, the most recent in 2025, and is an investigator in 28 clinical trials. SLR score: 425 (community average: 125). How the SLR is computed.

LeadR Profile

Marcus Hompesch ProSciento, Inc. United States
425 ScienceLeadR Reputation 425
Network Map

Internal medicine

Subspecialties: Endocrinology - Pharmacy - Hepatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Short Biography

University of Düsseldorf, Medical School. Training in Internal Medicine with particular interest in and focus on Diabetology, Diabetes Management and Clinical Research. After clinical and academic years transition into the clinical research industry. Taking entrepreneurial roles, initially focused on diabetes disease management software. Since 2000 exclusively involved in establishing and managing specialized, quality and science driven clinical research organizations, focused on early phase diabetes, MASH / MASLD, obesity drug and device development and patient engagement programs. Specialties: Early phase clinical drug and device development in Diabetes, MASH / MASLD and Obesity. Scientific expertise in designing phase 1 and 2 clinical studies with particular emphasis on meaningful (decision enabling) mechanistic and proof of concept studies.

Organizations

Career arc: 2006 - 2025

Source: PubMed

ProSciento, Inc.

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 106

Citations

Citations: 2 924 1st author: 12 Last author: 32 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Sustained Action of Imapextide, a Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers.
PMID 41437319 — endocrinology, glucagon-like peptide 1, injections, glucagon-like peptide-1 receptor, safety, pharmaceutical preparations, gastric emptying, healthy volunteers, bariatric surgery, glucagon, therapeutics, glucagon-like peptides
J Clin Endocrinol Metab20250
GLY-200, an oral pharmacologic duodenal exclusion drug, resulted in positive effects on glucose, lipids and bodyweight in patients with type 2 diabetes: Results of a randomized, double-blind placebo-controlled trial.
PMID 40767317 — diabetes mellitus, drug development, fasting, safety, pharmaceutical preparations, bariatric surgery, therapeutics, diabetes mellitus, type 2, weight control
Diabetes Obes Metab20250
A Randomized Controlled, Double-Masked, Crossover Study of a GPR119 Agonist on Glucagon Counterregulation During Hypoglycemia in Type 1 Diabetes.
PMID 40173094 — diabetes mellitus, glucagon-like peptide 1, cells, islets of langerhans, cross-over studies, epinephrine, glucagon, therapeutics, hypoglycemia, diabetes mellitus, type 1
Diabetes20250
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective.
PMID 39967239 — liver diseases, metabolic diseases, non-alcoholic fatty liver disease, liver, pharmacology, prevalence, therapeutics, diabetes mellitus, type 2
Aliment Pharmacol Ther20254
A phase 1, open-label, single-dose study to evaluate the pharmacokinetics (PK), safety and tolerability of HM15912 in subjects with severe renal impairment (RI) and normal renal function
OpenAlex W4402633743 — safety, pharmacokinetics
Clin Nutr ESPEN20240

Clinical Studies 28

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 9 Study Director: 2

By phase:

Phase 1 20
Phase 2 7
Phase 3 1

By status:

Completed 25
Unknown 3

By type:

Interventional 28

By Monocentric/Multicentric:

monocentric 25
multicentric2to4 2
multicentric5to9 0
multicentricup10 1

Main Topics

LeadR Networks

Main global connection map